nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—RPS6KB1—dilated cardiomyopathy	0.63	1	CbGaD
Crizotinib—EPHA2—pulmonary artery—dilated cardiomyopathy	0.00455	0.039	CbGeAlD
Crizotinib—SBK3—heart—dilated cardiomyopathy	0.00355	0.0305	CbGeAlD
Crizotinib—EPHA7—heart—dilated cardiomyopathy	0.0029	0.0248	CbGeAlD
Crizotinib—TESK1—Enalapril—Lisinopril—dilated cardiomyopathy	0.00277	1	CbGdCrCtD
Crizotinib—IKBKE—heart—dilated cardiomyopathy	0.0022	0.0188	CbGeAlD
Crizotinib—Dysaesthesia—Lisinopril—dilated cardiomyopathy	0.00167	0.0497	CcSEcCtD
Crizotinib—NEK9—heart—dilated cardiomyopathy	0.00157	0.0135	CbGeAlD
Crizotinib—PRKD1—heart—dilated cardiomyopathy	0.00143	0.0123	CbGeAlD
Crizotinib—LIMK1—heart—dilated cardiomyopathy	0.00141	0.0121	CbGeAlD
Crizotinib—FER—myocardium—dilated cardiomyopathy	0.0014	0.012	CbGeAlD
Crizotinib—PRKD3—heart—dilated cardiomyopathy	0.00138	0.0118	CbGeAlD
Crizotinib—DSTYK—heart—dilated cardiomyopathy	0.00135	0.0115	CbGeAlD
Crizotinib—CASK—heart—dilated cardiomyopathy	0.00132	0.0113	CbGeAlD
Crizotinib—TIE1—myocardium—dilated cardiomyopathy	0.00131	0.0112	CbGeAlD
Crizotinib—MAPK7—heart—dilated cardiomyopathy	0.00127	0.0109	CbGeAlD
Crizotinib—AURKA—myocardium—dilated cardiomyopathy	0.00127	0.0109	CbGeAlD
Crizotinib—ACVR1—cardiac ventricle—dilated cardiomyopathy	0.00126	0.0108	CbGeAlD
Crizotinib—TESK1—myocardium—dilated cardiomyopathy	0.00126	0.0108	CbGeAlD
Crizotinib—FES—heart—dilated cardiomyopathy	0.00126	0.0108	CbGeAlD
Crizotinib—STK35—cardiac ventricle—dilated cardiomyopathy	0.00124	0.0106	CbGeAlD
Crizotinib—Generalised oedema—Lisinopril—dilated cardiomyopathy	0.00121	0.0361	CcSEcCtD
Crizotinib—MET—heart—dilated cardiomyopathy	0.00119	0.0102	CbGeAlD
Crizotinib—ACVR1—myocardium—dilated cardiomyopathy	0.00119	0.0102	CbGeAlD
Crizotinib—STK35—myocardium—dilated cardiomyopathy	0.00116	0.00998	CbGeAlD
Crizotinib—CDK7—heart—dilated cardiomyopathy	0.00115	0.00989	CbGeAlD
Crizotinib—TAOK2—heart—dilated cardiomyopathy	0.00114	0.00981	CbGeAlD
Crizotinib—ACVR1B—heart—dilated cardiomyopathy	0.0011	0.00945	CbGeAlD
Crizotinib—EPHA3—heart—dilated cardiomyopathy	0.0011	0.00945	CbGeAlD
Crizotinib—RIPK2—myocardium—dilated cardiomyopathy	0.00107	0.0092	CbGeAlD
Crizotinib—TBK1—cardiac ventricle—dilated cardiomyopathy	0.00106	0.00909	CbGeAlD
Crizotinib—TYK2—cardiac ventricle—dilated cardiomyopathy	0.00105	0.00902	CbGeAlD
Crizotinib—JAK3—heart—dilated cardiomyopathy	0.00105	0.00902	CbGeAlD
Crizotinib—DCLK1—heart—dilated cardiomyopathy	0.00104	0.00896	CbGeAlD
Crizotinib—IRAK1—cardiac ventricle—dilated cardiomyopathy	0.00104	0.00891	CbGeAlD
Crizotinib—EPHA4—myocardium—dilated cardiomyopathy	0.00104	0.0089	CbGeAlD
Crizotinib—STK4—heart—dilated cardiomyopathy	0.00103	0.00885	CbGeAlD
Crizotinib—RPS6KB1—cardiac ventricle—dilated cardiomyopathy	0.00102	0.00874	CbGeAlD
Crizotinib—AXL—cardiac ventricle—dilated cardiomyopathy	0.00101	0.00865	CbGeAlD
Crizotinib—TBK1—myocardium—dilated cardiomyopathy	0.000997	0.00855	CbGeAlD
Crizotinib—PTK2—myocardium—dilated cardiomyopathy	0.000997	0.00855	CbGeAlD
Crizotinib—TYK2—myocardium—dilated cardiomyopathy	0.00099	0.00849	CbGeAlD
Crizotinib—IRAK1—myocardium—dilated cardiomyopathy	0.000977	0.00838	CbGeAlD
Crizotinib—FER—heart—dilated cardiomyopathy	0.000975	0.00837	CbGeAlD
Crizotinib—SLK—cardiac ventricle—dilated cardiomyopathy	0.000971	0.00833	CbGeAlD
Crizotinib—TNK1—heart—dilated cardiomyopathy	0.000965	0.00828	CbGeAlD
Crizotinib—EPHB4—cardiac ventricle—dilated cardiomyopathy	0.000964	0.00827	CbGeAlD
Crizotinib—RPS6KB1—myocardium—dilated cardiomyopathy	0.000959	0.00822	CbGeAlD
Crizotinib—JAK2—cardiac ventricle—dilated cardiomyopathy	0.000957	0.00821	CbGeAlD
Crizotinib—MAP4K1—heart—dilated cardiomyopathy	0.000956	0.0082	CbGeAlD
Crizotinib—AXL—myocardium—dilated cardiomyopathy	0.000949	0.00814	CbGeAlD
Crizotinib—TNK2—heart—dilated cardiomyopathy	0.000937	0.00804	CbGeAlD
Crizotinib—IGF1R—heart—dilated cardiomyopathy	0.000937	0.00804	CbGeAlD
Crizotinib—MAP4K2—heart—dilated cardiomyopathy	0.000924	0.00792	CbGeAlD
Crizotinib—TEK—cardiac ventricle—dilated cardiomyopathy	0.000923	0.00791	CbGeAlD
Crizotinib—MAP3K3—cardiac ventricle—dilated cardiomyopathy	0.000923	0.00791	CbGeAlD
Crizotinib—SLK—myocardium—dilated cardiomyopathy	0.000914	0.00783	CbGeAlD
Crizotinib—STK3—heart—dilated cardiomyopathy	0.000912	0.00782	CbGeAlD
Crizotinib—TIE1—heart—dilated cardiomyopathy	0.000912	0.00782	CbGeAlD
Crizotinib—EPHB4—myocardium—dilated cardiomyopathy	0.000907	0.00778	CbGeAlD
Crizotinib—JAK2—myocardium—dilated cardiomyopathy	0.000901	0.00772	CbGeAlD
Crizotinib—AURKA—heart—dilated cardiomyopathy	0.000888	0.00762	CbGeAlD
Crizotinib—TESK1—heart—dilated cardiomyopathy	0.000881	0.00756	CbGeAlD
Crizotinib—TEK—myocardium—dilated cardiomyopathy	0.000868	0.00744	CbGeAlD
Crizotinib—MAP3K3—myocardium—dilated cardiomyopathy	0.000868	0.00744	CbGeAlD
Crizotinib—MERTK—heart—dilated cardiomyopathy	0.000857	0.00735	CbGeAlD
Crizotinib—YES1—cardiac ventricle—dilated cardiomyopathy	0.000852	0.00731	CbGeAlD
Crizotinib—TAOK3—cardiac ventricle—dilated cardiomyopathy	0.000841	0.00721	CbGeAlD
Crizotinib—LIMK2—heart—dilated cardiomyopathy	0.000838	0.00719	CbGeAlD
Crizotinib—FER—cardiac atrium—dilated cardiomyopathy	0.000834	0.00715	CbGeAlD
Crizotinib—MAP3K12—heart—dilated cardiomyopathy	0.000829	0.00711	CbGeAlD
Crizotinib—ACVR1—heart—dilated cardiomyopathy	0.000829	0.00711	CbGeAlD
Crizotinib—FLT3—heart—dilated cardiomyopathy	0.000829	0.00711	CbGeAlD
Crizotinib—STK35—heart—dilated cardiomyopathy	0.000813	0.00697	CbGeAlD
Crizotinib—YES1—myocardium—dilated cardiomyopathy	0.000802	0.00687	CbGeAlD
Crizotinib—ABL2—heart—dilated cardiomyopathy	0.000792	0.00679	CbGeAlD
Crizotinib—TAOK3—myocardium—dilated cardiomyopathy	0.000791	0.00679	CbGeAlD
Crizotinib—BMP2K—heart—dilated cardiomyopathy	0.000782	0.00671	CbGeAlD
Crizotinib—TIE1—cardiac atrium—dilated cardiomyopathy	0.00078	0.00669	CbGeAlD
Crizotinib—PTK2B—heart—dilated cardiomyopathy	0.000755	0.00648	CbGeAlD
Crizotinib—TESK1—cardiac atrium—dilated cardiomyopathy	0.000754	0.00646	CbGeAlD
Crizotinib—RIPK2—heart—dilated cardiomyopathy	0.000749	0.00642	CbGeAlD
Crizotinib—EPHA4—heart—dilated cardiomyopathy	0.000724	0.00621	CbGeAlD
Crizotinib—Pulmonary embolism—Lisinopril—dilated cardiomyopathy	0.000722	0.0215	CcSEcCtD
Crizotinib—MAP3K2—heart—dilated cardiomyopathy	0.00071	0.00609	CbGeAlD
Crizotinib—ACVR1—cardiac atrium—dilated cardiomyopathy	0.000709	0.00608	CbGeAlD
Crizotinib—MAP3K12—cardiac atrium—dilated cardiomyopathy	0.000709	0.00608	CbGeAlD
Crizotinib—TBK1—heart—dilated cardiomyopathy	0.000696	0.00596	CbGeAlD
Crizotinib—PTK2—heart—dilated cardiomyopathy	0.000696	0.00596	CbGeAlD
Crizotinib—STK35—cardiac atrium—dilated cardiomyopathy	0.000695	0.00596	CbGeAlD
Crizotinib—Leukopenia—Spironolactone—dilated cardiomyopathy	0.000692	0.0206	CcSEcCtD
Crizotinib—TYK2—heart—dilated cardiomyopathy	0.000691	0.00592	CbGeAlD
Crizotinib—Fluid retention—Lisinopril—dilated cardiomyopathy	0.000686	0.0204	CcSEcCtD
Crizotinib—IRAK1—heart—dilated cardiomyopathy	0.000682	0.00585	CbGeAlD
Crizotinib—Photophobia—Lisinopril—dilated cardiomyopathy	0.000678	0.0202	CcSEcCtD
Crizotinib—Neuropathy—Lisinopril—dilated cardiomyopathy	0.000678	0.0202	CcSEcCtD
Crizotinib—RPS6KB1—heart—dilated cardiomyopathy	0.000669	0.00574	CbGeAlD
Crizotinib—FGR—heart—dilated cardiomyopathy	0.000665	0.0057	CbGeAlD
Crizotinib—LCK—heart—dilated cardiomyopathy	0.000665	0.0057	CbGeAlD
Crizotinib—AXL—heart—dilated cardiomyopathy	0.000662	0.00568	CbGeAlD
Crizotinib—RIPK2—cardiac atrium—dilated cardiomyopathy	0.000641	0.00549	CbGeAlD
Crizotinib—SLK—heart—dilated cardiomyopathy	0.000638	0.00547	CbGeAlD
Crizotinib—Hypokalaemia—Furosemide—dilated cardiomyopathy	0.000636	0.0189	CcSEcCtD
Crizotinib—EPHB4—heart—dilated cardiomyopathy	0.000633	0.00543	CbGeAlD
Crizotinib—JAK2—heart—dilated cardiomyopathy	0.000629	0.00539	CbGeAlD
Crizotinib—EPHA2—heart—dilated cardiomyopathy	0.000621	0.00533	CbGeAlD
Crizotinib—EPHA4—cardiac atrium—dilated cardiomyopathy	0.000619	0.00531	CbGeAlD
Crizotinib—Muscular weakness—Furosemide—dilated cardiomyopathy	0.000616	0.0183	CcSEcCtD
Crizotinib—MAP3K3—heart—dilated cardiomyopathy	0.000606	0.0052	CbGeAlD
Crizotinib—TEK—heart—dilated cardiomyopathy	0.000606	0.0052	CbGeAlD
Crizotinib—MAP4K5—heart—dilated cardiomyopathy	0.000606	0.0052	CbGeAlD
Crizotinib—Hepatic function abnormal—Lisinopril—dilated cardiomyopathy	0.0006	0.0179	CcSEcCtD
Crizotinib—TBK1—cardiac atrium—dilated cardiomyopathy	0.000595	0.0051	CbGeAlD
Crizotinib—TYK2—cardiac atrium—dilated cardiomyopathy	0.000591	0.00507	CbGeAlD
Crizotinib—Hepatic failure—Lisinopril—dilated cardiomyopathy	0.000583	0.0174	CcSEcCtD
Crizotinib—ABL1—cardiac ventricle—dilated cardiomyopathy	0.000582	0.00499	CbGeAlD
Crizotinib—EPHB6—heart—dilated cardiomyopathy	0.000579	0.00497	CbGeAlD
Crizotinib—RPS6KB1—cardiac atrium—dilated cardiomyopathy	0.000572	0.00491	CbGeAlD
Crizotinib—AXL—cardiac atrium—dilated cardiomyopathy	0.000567	0.00486	CbGeAlD
Crizotinib—YES1—heart—dilated cardiomyopathy	0.00056	0.0048	CbGeAlD
Crizotinib—STK10—heart—dilated cardiomyopathy	0.000554	0.00475	CbGeAlD
Crizotinib—TAOK3—heart—dilated cardiomyopathy	0.000552	0.00474	CbGeAlD
Crizotinib—ABL1—myocardium—dilated cardiomyopathy	0.000547	0.00469	CbGeAlD
Crizotinib—SLK—cardiac atrium—dilated cardiomyopathy	0.000545	0.00468	CbGeAlD
Crizotinib—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.000545	0.0162	CcSEcCtD
Crizotinib—EPHB4—cardiac atrium—dilated cardiomyopathy	0.000541	0.00464	CbGeAlD
Crizotinib—SRC—heart—dilated cardiomyopathy	0.000538	0.00462	CbGeAlD
Crizotinib—JAK2—cardiac atrium—dilated cardiomyopathy	0.000538	0.00461	CbGeAlD
Crizotinib—EPHA2—cardiac atrium—dilated cardiomyopathy	0.000531	0.00455	CbGeAlD
Crizotinib—Diplopia—Lisinopril—dilated cardiomyopathy	0.000524	0.0156	CcSEcCtD
Crizotinib—MAP3K3—cardiac atrium—dilated cardiomyopathy	0.000518	0.00444	CbGeAlD
Crizotinib—MAP4K5—cardiac atrium—dilated cardiomyopathy	0.000518	0.00444	CbGeAlD
Crizotinib—TEK—cardiac atrium—dilated cardiomyopathy	0.000518	0.00444	CbGeAlD
Crizotinib—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.000509	0.0152	CcSEcCtD
Crizotinib—Face oedema—Lisinopril—dilated cardiomyopathy	0.000506	0.0151	CcSEcCtD
Crizotinib—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.000499	0.0149	CcSEcCtD
Crizotinib—EPHB6—cardiac atrium—dilated cardiomyopathy	0.000495	0.00425	CbGeAlD
Crizotinib—CSF1R—heart—dilated cardiomyopathy	0.000483	0.00414	CbGeAlD
Crizotinib—YES1—cardiac atrium—dilated cardiomyopathy	0.000479	0.0041	CbGeAlD
Crizotinib—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.000477	0.0142	CcSEcCtD
Crizotinib—Urethral disorder—Furosemide—dilated cardiomyopathy	0.000474	0.0141	CcSEcCtD
Crizotinib—TAOK3—cardiac atrium—dilated cardiomyopathy	0.000472	0.00405	CbGeAlD
Crizotinib—Visual impairment—Furosemide—dilated cardiomyopathy	0.000466	0.0139	CcSEcCtD
Crizotinib—SRC—cardiac atrium—dilated cardiomyopathy	0.00046	0.00395	CbGeAlD
Crizotinib—Eye disorder—Furosemide—dilated cardiomyopathy	0.000452	0.0134	CcSEcCtD
Crizotinib—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.000432	0.0129	CcSEcCtD
Crizotinib—Arrhythmia—Furosemide—dilated cardiomyopathy	0.000432	0.0129	CcSEcCtD
Crizotinib—Neutropenia—Lisinopril—dilated cardiomyopathy	0.000424	0.0126	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.000421	0.0125	CcSEcCtD
Crizotinib—Malnutrition—Furosemide—dilated cardiomyopathy	0.000421	0.0125	CcSEcCtD
Crizotinib—Dizziness—Spironolactone—dilated cardiomyopathy	0.000417	0.0124	CcSEcCtD
Crizotinib—CSF1R—cardiac atrium—dilated cardiomyopathy	0.000413	0.00354	CbGeAlD
Crizotinib—Dysgeusia—Furosemide—dilated cardiomyopathy	0.000412	0.0123	CcSEcCtD
Crizotinib—Weight decreased—Lisinopril—dilated cardiomyopathy	0.00041	0.0122	CcSEcCtD
Crizotinib—Pneumonia—Lisinopril—dilated cardiomyopathy	0.000406	0.0121	CcSEcCtD
Crizotinib—Vomiting—Spironolactone—dilated cardiomyopathy	0.000401	0.0119	CcSEcCtD
Crizotinib—Rash—Spironolactone—dilated cardiomyopathy	0.000398	0.0118	CcSEcCtD
Crizotinib—Dermatitis—Spironolactone—dilated cardiomyopathy	0.000398	0.0118	CcSEcCtD
Crizotinib—Vision blurred—Furosemide—dilated cardiomyopathy	0.000396	0.0118	CcSEcCtD
Crizotinib—Neuropathy peripheral—Lisinopril—dilated cardiomyopathy	0.000396	0.0118	CcSEcCtD
Crizotinib—Anaemia—Furosemide—dilated cardiomyopathy	0.000389	0.0116	CcSEcCtD
Crizotinib—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.000382	0.0114	CcSEcCtD
Crizotinib—ABL1—heart—dilated cardiomyopathy	0.000382	0.00328	CbGeAlD
Crizotinib—Leukopenia—Furosemide—dilated cardiomyopathy	0.000377	0.0112	CcSEcCtD
Crizotinib—Nausea—Spironolactone—dilated cardiomyopathy	0.000375	0.0112	CcSEcCtD
Crizotinib—Bradycardia—Lisinopril—dilated cardiomyopathy	0.000369	0.011	CcSEcCtD
Crizotinib—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.000358	0.0107	CcSEcCtD
Crizotinib—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.000357	0.0106	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.000356	0.0106	CcSEcCtD
Crizotinib—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.000355	0.0106	CcSEcCtD
Crizotinib—Shock—Furosemide—dilated cardiomyopathy	0.000338	0.0101	CcSEcCtD
Crizotinib—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.000337	0.01	CcSEcCtD
Crizotinib—Skin disorder—Furosemide—dilated cardiomyopathy	0.000334	0.00993	CcSEcCtD
Crizotinib—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.000327	0.00973	CcSEcCtD
Crizotinib—ABL1—cardiac atrium—dilated cardiomyopathy	0.000327	0.0028	CbGeAlD
Crizotinib—Arrhythmia—Lisinopril—dilated cardiomyopathy	0.000324	0.00964	CcSEcCtD
Crizotinib—Malnutrition—Lisinopril—dilated cardiomyopathy	0.000316	0.0094	CcSEcCtD
Crizotinib—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.000309	0.0092	CcSEcCtD
Crizotinib—Paraesthesia—Furosemide—dilated cardiomyopathy	0.000308	0.00918	CcSEcCtD
Crizotinib—Decreased appetite—Furosemide—dilated cardiomyopathy	0.000298	0.00889	CcSEcCtD
Crizotinib—Vision blurred—Lisinopril—dilated cardiomyopathy	0.000297	0.00886	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.000296	0.00883	CcSEcCtD
Crizotinib—Fatigue—Furosemide—dilated cardiomyopathy	0.000296	0.00881	CcSEcCtD
Crizotinib—Constipation—Furosemide—dilated cardiomyopathy	0.000294	0.00874	CcSEcCtD
Crizotinib—Anaemia—Lisinopril—dilated cardiomyopathy	0.000292	0.00869	CcSEcCtD
Crizotinib—Syncope—Lisinopril—dilated cardiomyopathy	0.000283	0.00843	CcSEcCtD
Crizotinib—Leukopenia—Lisinopril—dilated cardiomyopathy	0.000283	0.00841	CcSEcCtD
Crizotinib—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.000277	0.00826	CcSEcCtD
Crizotinib—Body temperature increased—Furosemide—dilated cardiomyopathy	0.000271	0.00808	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.000267	0.00795	CcSEcCtD
Crizotinib—Oedema—Lisinopril—dilated cardiomyopathy	0.000258	0.00767	CcSEcCtD
Crizotinib—Infection—Lisinopril—dilated cardiomyopathy	0.000256	0.00762	CcSEcCtD
Crizotinib—Shock—Lisinopril—dilated cardiomyopathy	0.000253	0.00755	CcSEcCtD
Crizotinib—Skin disorder—Lisinopril—dilated cardiomyopathy	0.00025	0.00745	CcSEcCtD
Crizotinib—Asthenia—Furosemide—dilated cardiomyopathy	0.000246	0.00733	CcSEcCtD
Crizotinib—Diarrhoea—Furosemide—dilated cardiomyopathy	0.000235	0.00699	CcSEcCtD
Crizotinib—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.000231	0.00689	CcSEcCtD
Crizotinib—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.00023	0.00684	CcSEcCtD
Crizotinib—Dizziness—Furosemide—dilated cardiomyopathy	0.000227	0.00676	CcSEcCtD
Crizotinib—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.000227	0.00675	CcSEcCtD
Crizotinib—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.000224	0.00667	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.000222	0.00662	CcSEcCtD
Crizotinib—Fatigue—Lisinopril—dilated cardiomyopathy	0.000222	0.00661	CcSEcCtD
Crizotinib—Constipation—Lisinopril—dilated cardiomyopathy	0.00022	0.00656	CcSEcCtD
Crizotinib—Vomiting—Furosemide—dilated cardiomyopathy	0.000218	0.0065	CcSEcCtD
Crizotinib—Rash—Furosemide—dilated cardiomyopathy	0.000216	0.00645	CcSEcCtD
Crizotinib—Dermatitis—Furosemide—dilated cardiomyopathy	0.000216	0.00644	CcSEcCtD
Crizotinib—Nausea—Furosemide—dilated cardiomyopathy	0.000204	0.00607	CcSEcCtD
Crizotinib—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.000204	0.00606	CcSEcCtD
Crizotinib—Asthenia—Lisinopril—dilated cardiomyopathy	0.000185	0.0055	CcSEcCtD
Crizotinib—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000176	0.00525	CcSEcCtD
Crizotinib—Dizziness—Lisinopril—dilated cardiomyopathy	0.00017	0.00507	CcSEcCtD
Crizotinib—Vomiting—Lisinopril—dilated cardiomyopathy	0.000164	0.00488	CcSEcCtD
Crizotinib—Rash—Lisinopril—dilated cardiomyopathy	0.000162	0.00484	CcSEcCtD
Crizotinib—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000162	0.00483	CcSEcCtD
Crizotinib—Nausea—Lisinopril—dilated cardiomyopathy	0.000153	0.00456	CcSEcCtD
Crizotinib—ABCB1—heart—dilated cardiomyopathy	0.000119	0.00102	CbGeAlD
Crizotinib—ABL1—Developmental Biology—RAF1—dilated cardiomyopathy	7.17e-06	3.3e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by NGF—EGFR—dilated cardiomyopathy	7.16e-06	3.3e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—RAF1—dilated cardiomyopathy	7.13e-06	3.28e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—RAC1—dilated cardiomyopathy	7.11e-06	3.28e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—CD36—dilated cardiomyopathy	7.1e-06	3.27e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—ADRB1—dilated cardiomyopathy	7.09e-06	3.27e-05	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—RAF1—dilated cardiomyopathy	7.07e-06	3.26e-05	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—RAF1—dilated cardiomyopathy	7.03e-06	3.24e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—RAC1—dilated cardiomyopathy	7.03e-06	3.24e-05	CbGpPWpGaD
Crizotinib—BLK—Adaptive Immune System—EGFR—dilated cardiomyopathy	6.98e-06	3.22e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—RAC1—dilated cardiomyopathy	6.96e-06	3.21e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—ITGB1—dilated cardiomyopathy	6.95e-06	3.2e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	6.93e-06	3.19e-05	CbGpPWpGaD
Crizotinib—LYN—Axon guidance—EGFR—dilated cardiomyopathy	6.92e-06	3.19e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—ITGB1—dilated cardiomyopathy	6.92e-06	3.19e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—RAC1—dilated cardiomyopathy	6.9e-06	3.18e-05	CbGpPWpGaD
Crizotinib—ABL1—Axon guidance—EGFR—dilated cardiomyopathy	6.89e-06	3.17e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	6.83e-06	3.15e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—RAF1—dilated cardiomyopathy	6.74e-06	3.11e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PSEN2—dilated cardiomyopathy	6.72e-06	3.1e-05	CbGpPWpGaD
Crizotinib—PTK2—Developmental Biology—EGFR—dilated cardiomyopathy	6.72e-06	3.1e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—AGT—dilated cardiomyopathy	6.71e-06	3.09e-05	CbGpPWpGaD
Crizotinib—MAPK7—Immune System—EGFR—dilated cardiomyopathy	6.69e-06	3.08e-05	CbGpPWpGaD
Crizotinib—LIMK1—Immune System—EGFR—dilated cardiomyopathy	6.69e-06	3.08e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—RAC1—dilated cardiomyopathy	6.69e-06	3.08e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—AGTR1—dilated cardiomyopathy	6.67e-06	3.07e-05	CbGpPWpGaD
Crizotinib—YES1—Developmental Biology—EGFR—dilated cardiomyopathy	6.63e-06	3.05e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	6.61e-06	3.05e-05	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—RAF1—dilated cardiomyopathy	6.61e-06	3.05e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—AGTR1—dilated cardiomyopathy	6.58e-06	3.03e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	6.54e-06	3.01e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—ITGB1—dilated cardiomyopathy	6.51e-06	3e-05	CbGpPWpGaD
Crizotinib—JAK2—Axon guidance—EGFR—dilated cardiomyopathy	6.48e-06	2.98e-05	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—EGFR—dilated cardiomyopathy	6.45e-06	2.97e-05	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—EGFR—dilated cardiomyopathy	6.45e-06	2.97e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—RAF1—dilated cardiomyopathy	6.44e-06	2.97e-05	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—RAF1—dilated cardiomyopathy	6.42e-06	2.96e-05	CbGpPWpGaD
Crizotinib—PTK2—Developmental Biology—TNF—dilated cardiomyopathy	6.4e-06	2.95e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CXCL2—dilated cardiomyopathy	6.38e-06	2.94e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—AGTR2—dilated cardiomyopathy	6.38e-06	2.94e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—RAC1—dilated cardiomyopathy	6.37e-06	2.94e-05	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—RAF1—dilated cardiomyopathy	6.36e-06	2.93e-05	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—RAF1—dilated cardiomyopathy	6.33e-06	2.92e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—ADRB2—dilated cardiomyopathy	6.33e-06	2.92e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—RAF1—dilated cardiomyopathy	6.33e-06	2.92e-05	CbGpPWpGaD
Crizotinib—YES1—Developmental Biology—TNF—dilated cardiomyopathy	6.31e-06	2.91e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—RAF1—dilated cardiomyopathy	6.31e-06	2.91e-05	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—RAC1—dilated cardiomyopathy	6.3e-06	2.9e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling by NGF—EGFR—dilated cardiomyopathy	6.27e-06	2.89e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—RAC1—dilated cardiomyopathy	6.26e-06	2.89e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—ADRB2—dilated cardiomyopathy	6.24e-06	2.88e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—AGTR1—dilated cardiomyopathy	6.24e-06	2.88e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—RAF1—dilated cardiomyopathy	6.22e-06	2.86e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—RAF1—dilated cardiomyopathy	6.18e-06	2.85e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—RAC1—dilated cardiomyopathy	6.17e-06	2.84e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—RAF1—dilated cardiomyopathy	6.16e-06	2.84e-05	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—EGFR—dilated cardiomyopathy	6.11e-06	2.82e-05	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—RAF1—dilated cardiomyopathy	6.11e-06	2.81e-05	CbGpPWpGaD
Crizotinib—TYK2—Developmental Biology—EGFR—dilated cardiomyopathy	6.1e-06	2.81e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—AGTR1—dilated cardiomyopathy	6.06e-06	2.79e-05	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—AGT—dilated cardiomyopathy	6.02e-06	2.77e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—AGT—dilated cardiomyopathy	5.98e-06	2.76e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CXCL2—dilated cardiomyopathy	5.97e-06	2.75e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—AGTR2—dilated cardiomyopathy	5.97e-06	2.75e-05	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—RAF1—dilated cardiomyopathy	5.95e-06	2.74e-05	CbGpPWpGaD
Crizotinib—PTK2—Innate Immune System—EGFR—dilated cardiomyopathy	5.93e-06	2.73e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CXCR3—dilated cardiomyopathy	5.93e-06	2.73e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—CD36—dilated cardiomyopathy	5.93e-06	2.73e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—ADRB2—dilated cardiomyopathy	5.92e-06	2.73e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—RAC1—dilated cardiomyopathy	5.91e-06	2.72e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CD36—dilated cardiomyopathy	5.9e-06	2.72e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—AGT—dilated cardiomyopathy	5.9e-06	2.72e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PSEN2—dilated cardiomyopathy	5.89e-06	2.71e-05	CbGpPWpGaD
Crizotinib—YES1—Innate Immune System—EGFR—dilated cardiomyopathy	5.85e-06	2.7e-05	CbGpPWpGaD
Crizotinib—TYK2—Developmental Biology—TNF—dilated cardiomyopathy	5.81e-06	2.68e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—RAF1—dilated cardiomyopathy	5.79e-06	2.67e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—ADRB2—dilated cardiomyopathy	5.75e-06	2.65e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—ADRB1—dilated cardiomyopathy	5.74e-06	2.65e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—RAC1—dilated cardiomyopathy	5.73e-06	2.64e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—RAC1—dilated cardiomyopathy	5.72e-06	2.64e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—ITGB1—dilated cardiomyopathy	5.7e-06	2.63e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—AGT—dilated cardiomyopathy	5.64e-06	2.6e-05	CbGpPWpGaD
Crizotinib—YES1—Adaptive Immune System—EGFR—dilated cardiomyopathy	5.62e-06	2.59e-05	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—EGFR—dilated cardiomyopathy	5.59e-06	2.58e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—RAC1—dilated cardiomyopathy	5.59e-06	2.57e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—RAC1—dilated cardiomyopathy	5.56e-06	2.56e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling by NGF—EGFR—dilated cardiomyopathy	5.55e-06	2.56e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CXCR3—dilated cardiomyopathy	5.55e-06	2.56e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CD36—dilated cardiomyopathy	5.55e-06	2.56e-05	CbGpPWpGaD
Crizotinib—IRAK1—Innate Immune System—EGFR—dilated cardiomyopathy	5.55e-06	2.56e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—AGT—dilated cardiomyopathy	5.47e-06	2.52e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—AGT—dilated cardiomyopathy	5.47e-06	2.52e-05	CbGpPWpGaD
Crizotinib—TBK1—Immune System—EGFR—dilated cardiomyopathy	5.46e-06	2.52e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	5.44e-06	2.51e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling by GPCR—EGFR—dilated cardiomyopathy	5.41e-06	2.49e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	5.39e-06	2.48e-05	CbGpPWpGaD
Crizotinib—TYK2—Innate Immune System—EGFR—dilated cardiomyopathy	5.39e-06	2.48e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—ADRB1—dilated cardiomyopathy	5.38e-06	2.48e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	5.36e-06	2.47e-05	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—EGFR—dilated cardiomyopathy	5.24e-06	2.41e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—RAC1—dilated cardiomyopathy	5.23e-06	2.41e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—AGTR2—dilated cardiomyopathy	5.23e-06	2.41e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CXCL2—dilated cardiomyopathy	5.23e-06	2.41e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—RAF1—dilated cardiomyopathy	5.23e-06	2.41e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—RAF1—dilated cardiomyopathy	5.22e-06	2.4e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PSEN2—dilated cardiomyopathy	5.21e-06	2.4e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—RAF1—dilated cardiomyopathy	5.13e-06	2.36e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	5.09e-06	2.34e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	5.07e-06	2.34e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—ITGB1—dilated cardiomyopathy	5.05e-06	2.32e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—RAF1—dilated cardiomyopathy	5.04e-06	2.32e-05	CbGpPWpGaD
Crizotinib—SRC—Axon guidance—EGFR—dilated cardiomyopathy	5.02e-06	2.31e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—RAF1—dilated cardiomyopathy	5.01e-06	2.31e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—RAF1—dilated cardiomyopathy	5.01e-06	2.31e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—RAF1—dilated cardiomyopathy	4.97e-06	2.29e-05	CbGpPWpGaD
Crizotinib—JAK3—Immune System—EGFR—dilated cardiomyopathy	4.94e-06	2.28e-05	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—EGFR—dilated cardiomyopathy	4.94e-06	2.28e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	4.94e-06	2.28e-05	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—EGFR—dilated cardiomyopathy	4.92e-06	2.27e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—RAC1—dilated cardiomyopathy	4.91e-06	2.26e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—AGTR1—dilated cardiomyopathy	4.91e-06	2.26e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—EGFR—dilated cardiomyopathy	4.89e-06	2.25e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CXCR3—dilated cardiomyopathy	4.86e-06	2.24e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—CD36—dilated cardiomyopathy	4.86e-06	2.24e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—RAC1—dilated cardiomyopathy	4.85e-06	2.23e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—RAC1—dilated cardiomyopathy	4.83e-06	2.22e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—RAF1—dilated cardiomyopathy	4.71e-06	2.17e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—ADRB1—dilated cardiomyopathy	4.71e-06	2.17e-05	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—TNF—dilated cardiomyopathy	4.71e-06	2.17e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—AGT—dilated cardiomyopathy	4.69e-06	2.16e-05	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—TNF—dilated cardiomyopathy	4.68e-06	2.16e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—RAF1—dilated cardiomyopathy	4.66e-06	2.15e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—ADRB2—dilated cardiomyopathy	4.65e-06	2.14e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—AGT—dilated cardiomyopathy	4.63e-06	2.13e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CXCL2—dilated cardiomyopathy	4.63e-06	2.13e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—AGTR2—dilated cardiomyopathy	4.63e-06	2.13e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—EGFR—dilated cardiomyopathy	4.62e-06	2.13e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—RAF1—dilated cardiomyopathy	4.62e-06	2.13e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—RAC1—dilated cardiomyopathy	4.6e-06	2.12e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—AGTR1—dilated cardiomyopathy	4.59e-06	2.12e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	4.58e-06	2.11e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—RAC1—dilated cardiomyopathy	4.58e-06	2.11e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—RAF1—dilated cardiomyopathy	4.58e-06	2.11e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	4.54e-06	2.09e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—RAC1—dilated cardiomyopathy	4.46e-06	2.06e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—RAF1—dilated cardiomyopathy	4.43e-06	2.04e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—EGFR—dilated cardiomyopathy	4.42e-06	2.04e-05	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—EGFR—dilated cardiomyopathy	4.4e-06	2.03e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—TNF—dilated cardiomyopathy	4.4e-06	2.03e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—AGT—dilated cardiomyopathy	4.39e-06	2.02e-05	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—EGFR—dilated cardiomyopathy	4.36e-06	2.01e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—ADRB2—dilated cardiomyopathy	4.36e-06	2.01e-05	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—EGFR—dilated cardiomyopathy	4.34e-06	2e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—EGFR—dilated cardiomyopathy	4.34e-06	2e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—EGFR—dilated cardiomyopathy	4.32e-06	1.99e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	4.32e-06	1.99e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CXCR3—dilated cardiomyopathy	4.3e-06	1.98e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—CD36—dilated cardiomyopathy	4.3e-06	1.98e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—AGT—dilated cardiomyopathy	4.26e-06	1.96e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—EGFR—dilated cardiomyopathy	4.26e-06	1.96e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—EGFR—dilated cardiomyopathy	4.24e-06	1.95e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—RAC1—dilated cardiomyopathy	4.23e-06	1.95e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—RAF1—dilated cardiomyopathy	4.22e-06	1.95e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—EGFR—dilated cardiomyopathy	4.22e-06	1.95e-05	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—EGFR—dilated cardiomyopathy	4.19e-06	1.93e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—ADRB1—dilated cardiomyopathy	4.17e-06	1.92e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—RAF1—dilated cardiomyopathy	4.15e-06	1.91e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—RAF1—dilated cardiomyopathy	4.09e-06	1.89e-05	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—EGFR—dilated cardiomyopathy	4.08e-06	1.88e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—RAC1—dilated cardiomyopathy	4.06e-06	1.87e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—AGTR1—dilated cardiomyopathy	4.02e-06	1.85e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	4e-06	1.84e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—RAF1—dilated cardiomyopathy	3.92e-06	1.8e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—ADRB2—dilated cardiomyopathy	3.82e-06	1.76e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—RAF1—dilated cardiomyopathy	3.8e-06	1.75e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—RAF1—dilated cardiomyopathy	3.8e-06	1.75e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—RAC1—dilated cardiomyopathy	3.74e-06	1.73e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	3.74e-06	1.72e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—RAF1—dilated cardiomyopathy	3.71e-06	1.71e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—RAF1—dilated cardiomyopathy	3.69e-06	1.7e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—RAC1—dilated cardiomyopathy	3.61e-06	1.66e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—EGFR—dilated cardiomyopathy	3.58e-06	1.65e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—EGFR—dilated cardiomyopathy	3.58e-06	1.65e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—AGTR1—dilated cardiomyopathy	3.56e-06	1.64e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—RAF1—dilated cardiomyopathy	3.47e-06	1.6e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—EGFR—dilated cardiomyopathy	3.46e-06	1.59e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—AGT—dilated cardiomyopathy	3.45e-06	1.59e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—EGFR—dilated cardiomyopathy	3.43e-06	1.58e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—EGFR—dilated cardiomyopathy	3.43e-06	1.58e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—TNF—dilated cardiomyopathy	3.41e-06	1.57e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—EGFR—dilated cardiomyopathy	3.41e-06	1.57e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—RAC1—dilated cardiomyopathy	3.38e-06	1.56e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—ADRB2—dilated cardiomyopathy	3.38e-06	1.56e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	3.28e-06	1.51e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—RAF1—dilated cardiomyopathy	3.26e-06	1.5e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—EGFR—dilated cardiomyopathy	3.23e-06	1.49e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—AGT—dilated cardiomyopathy	3.23e-06	1.49e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—RAF1—dilated cardiomyopathy	3.21e-06	1.48e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—RAF1—dilated cardiomyopathy	3.2e-06	1.48e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—EGFR—dilated cardiomyopathy	3.19e-06	1.47e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—EGFR—dilated cardiomyopathy	3.17e-06	1.46e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—EGFR—dilated cardiomyopathy	3.14e-06	1.45e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—RAF1—dilated cardiomyopathy	3.05e-06	1.4e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—EGFR—dilated cardiomyopathy	3.04e-06	1.4e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—RAF1—dilated cardiomyopathy	3.04e-06	1.4e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—RAC1—dilated cardiomyopathy	2.96e-06	1.36e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—RAF1—dilated cardiomyopathy	2.96e-06	1.36e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.9e-06	1.34e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—EGFR—dilated cardiomyopathy	2.9e-06	1.33e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—EGFR—dilated cardiomyopathy	2.85e-06	1.31e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—AGT—dilated cardiomyopathy	2.83e-06	1.3e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—EGFR—dilated cardiomyopathy	2.81e-06	1.29e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—RAF1—dilated cardiomyopathy	2.8e-06	1.29e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—RAF1—dilated cardiomyopathy	2.69e-06	1.24e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—EGFR—dilated cardiomyopathy	2.69e-06	1.24e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—GPX1—dilated cardiomyopathy	2.68e-06	1.23e-05	CbGpPWpGaD
Crizotinib—ABCB1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	2.63e-06	1.21e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—RAC1—dilated cardiomyopathy	2.62e-06	1.21e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CD36—dilated cardiomyopathy	2.61e-06	1.2e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—EGFR—dilated cardiomyopathy	2.6e-06	1.2e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—EGFR—dilated cardiomyopathy	2.6e-06	1.2e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—EGFR—dilated cardiomyopathy	2.54e-06	1.17e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—EGFR—dilated cardiomyopathy	2.53e-06	1.17e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—AGT—dilated cardiomyopathy	2.51e-06	1.15e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—RAF1—dilated cardiomyopathy	2.48e-06	1.14e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—RAF1—dilated cardiomyopathy	2.4e-06	1.1e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—EGFR—dilated cardiomyopathy	2.38e-06	1.1e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—AGT—dilated cardiomyopathy	2.35e-06	1.08e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—RAF1—dilated cardiomyopathy	2.24e-06	1.03e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—EGFR—dilated cardiomyopathy	2.23e-06	1.03e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—EGFR—dilated cardiomyopathy	2.2e-06	1.02e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—EGFR—dilated cardiomyopathy	2.2e-06	1.01e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—EGFR—dilated cardiomyopathy	2.09e-06	9.63e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—EGFR—dilated cardiomyopathy	2.08e-06	9.6e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—EGFR—dilated cardiomyopathy	2.03e-06	9.35e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GPX1—dilated cardiomyopathy	2.02e-06	9.31e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CD36—dilated cardiomyopathy	1.97e-06	9.07e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—RAF1—dilated cardiomyopathy	1.96e-06	9.05e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—EGFR—dilated cardiomyopathy	1.92e-06	8.86e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—EGFR—dilated cardiomyopathy	1.84e-06	8.5e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—AGT—dilated cardiomyopathy	1.77e-06	8.17e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—RAF1—dilated cardiomyopathy	1.74e-06	8.01e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—EGFR—dilated cardiomyopathy	1.7e-06	7.84e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—EGFR—dilated cardiomyopathy	1.64e-06	7.57e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—EGFR—dilated cardiomyopathy	1.54e-06	7.08e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—EGFR—dilated cardiomyopathy	1.35e-06	6.2e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	1.25e-06	5.74e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	1.21e-06	5.59e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—EGFR—dilated cardiomyopathy	1.19e-06	5.49e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	1.09e-06	5.03e-06	CbGpPWpGaD
